Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze KYMR Kymera Therapeutics, Inc.. Please read: https://finlab.finance/en/setup?stock=KYMR

No install, write strategies with AI

KYMR

Kymera Therapeutics, Inc. Healthcare As of 2026-07-01

quality needs a look, discounted valuation.

2 active signals
52-week adjusted-price high Top-quintile 6-month momentum
Kymera Therapeutics, Inc. recent adjusted price trend，Close (USD) 114.2，60-day +33.93%114.260-day +33.93%

Is Kymera Therapeutics, Inc. a buy? Fundamentals and valuation first

Valuation 64Quality 13Growth 43Momentum 89Risk / liquidity 63

  • Quality is weaker than peers. Operating margin is only around the 6th percentile. TTM ROE is about -20.5%.

  • Valuation is cheaper than most peers. TTM P/E is in the 8th percentile, lower than most liquid US common stocks.

  • Recent volatility is moderate. 60-day annualized volatility is near the 61th percentile. Average 20-day dollar volume is about $130.2M.

  • Signals are active now. 52-week adjusted-price high, Top-quintile 6-month momentum currently holds; the tables below show what followed in this stock’s own history.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

8 historical occurrences (since 2024-02-09)
Average forward return after 52-week adjusted-price high。20-day: Win 57.1%, Sample 7, Median +0.99%, Excess +5.48%, Beat mkt rate 42.9%；60-day: Win 42.9%, Sample 7, Median -4.36%, Excess +1.52%, Beat mkt rate 42.9%；120-day: Win 50%, Sample 6, Median +2.7%, Excess +1.34%, Beat mkt rate 50%

120 days after: historical avg +6.16%

20-day +4.97%
60-day +5.64%
120-day +6.16%
20-day
60-day
120-day
Win
57.1%
42.9%
50%
Sample
7
7
6
Median
+0.99%
-4.36%
+2.7%
Excess
+5.48%
+1.52%
+1.34%
Beat mkt rate
42.9%
42.9%
50%

Over 6 occurrences, 120-day forward avg gained 6.16%, beat the market by 1.34 pts; win rate 50%.

Top-quintile 6-month momentum

Active · now 81.32530120481928%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

14 historical occurrences (since 2021-02-24)
Average forward return after Top-quintile 6-month momentum。20-day: Win 38.5%, Sample 13, Median -1.51%, Excess +0.39%, Beat mkt rate 46.2%；60-day: Win 58.3%, Sample 12, Median +6.96%, Excess +5.25%, Beat mkt rate 50%；120-day: Win 50%, Sample 12, Median +3.59%, Excess -0.99%, Beat mkt rate 41.7%

120 days after: historical avg +5.7%

20-day +2.36%
60-day +9.23%
120-day +5.7%
20-day
60-day
120-day
Win
38.5%
58.3%
50%
Sample
13
12
12
Median
-1.51%
+6.96%
+3.59%
Excess
+0.39%
+5.25%
-0.99%
Beat mkt rate
46.2%
50%
41.7%

Over 12 occurrences, 120-day forward avg gained 5.7%, lagged the market by 0.99 pts; win rate 50%.

Market-wide momentum baseline

Across 94,449 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.41%, a 58.3% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.